Regeneron price target lowered to $645 from $686 at Leerink
Leerink lowered the firm's price target on Regeneron (REGN) to $645 from $686 and keeps an Outperform rating on the shares. In the wake of itepekimab's failure in one of two Phase 3 COPD trials, the firm is removing the drug from its model and lowering its price target on the shares, the analyst tells investors in a research note. The firm noted that its investment thesis is that Regeneron shares can outperform from current levels because it expects growth to accelerate after a big Eylea sales/earnings stepdown in 2025; pipeline newsflow is likely to improve after several months of disappointing press releases, and; shares are trading near historical low multiple levels. The company should return to growth in 2026 and accelerate in 2027, the analyst adds.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Regeneron Launches $200 Million Donation Matching Program to Support Vision Care
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential. On June 24, Regeneron Pharmaceuticals announced a new and pioneering donation matching program to support Good Days, which is an independent national non-profit charitable organization. The initiative is designed to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this program, Regeneron has committed to matching donations at a one-to-one rate, up to a total of $200 million, for the remainder of the 2025 calendar year. The primary goal is to enable more patients to afford essential medicines that help protect their vision. The Retinal Vascular and Neovascular Disease Fund provides copay assistance to US patients who meet specific criteria determined by Good Days. A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. The donations are not intended to incentivize the use of any particular product, and copay support is granted without regard to the specific medicine prescribed, as long as it is FDA-approved. Regeneron also facilitates access to medicines through various other initiatives, such as product support & Managed Access Programs, patient assistance programs, and collaborations with experienced stakeholders. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Business Upturn
2 days ago
- Business Upturn
Biocon subsidiary gets Health Canada nod for YESAFILI
By Aman Shukla Published on June 27, 2025, 09:19 IST Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., has received a Notice of Compliance from Health Canada for YESAFILI™ (aflibercept), marking a significant milestone in the company's global biosimilars journey. The regulatory approval, granted on June 26, 2025, makes YESAFILI the first biosimilar to EYLEA® (aflibercept) to be approved in Canada. The product will be available in both vial and prefilled syringe forms (2 mg/0.05 mL), with its commercial launch set for July 4, 2025. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor designed to treat several serious eye conditions. These include neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and visual impairment due to macular edema caused by retinal vein occlusion (CRVO and BRVO), as well as myopic choroidal neovascularization (myopic CNV). The approval is backed by a robust data package encompassing analytical, nonclinical, and clinical studies. Health Canada concluded that YESAFILI matches EYLEA in quality, safety, and effectiveness, with no clinically meaningful differences. This milestone not only reinforces Biocon Biologics' capabilities in developing high-quality biosimilars but also enhances patient access to affordable treatment options in Canada. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
2 days ago
- Yahoo
Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025
TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for Yesafili™ (aflibercept), a biosimilar to Eylea® (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025. This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (wet) age-related macular degeneration (AMD) Visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) Visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) Diabetic macular edema (DME) Myopic choroidal neovascularization (myopic CNV) The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, confirming that YESAFILI is highly similar with no clinically meaningful differences to EYLEA in terms of quality, safety, and efficacy. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: 'The approval of YESAFILI by Health Canada—the first biosimilar to EYLEA® in Canada—is a proud moment for Biocon Biologics. We are excited that in July, Canada will be the first country where we will launch YESAFILI, making it our 10th biosimilar to be commercialized worldwide. This milestone reflects our science-driven innovation, global commercialization strength, and continued commitment to expanding access to high-quality, affordable biologics for patients across the globe.' Ramy Ayad, Head of Canada at Biocon Biologics, stated: 'This is a significant achievement for Biocon Biologics in Canada. With the approval of YESAFILI, we are delivering on our promise to improve access to advanced biologic therapies. Canadian ophthalmologists and patients will soon have a high-quality, affordable biosimilar option for serious retinal diseases.' About YESAFILI™:The approval for YESAFILI (aflibercept) was based on a comprehensive package of analytical, nonclinical, and clinical data, which confirmed that YESAFILI is highly similar to EYLEA. In a Phase 3 INSIGHT Study, YESAFILI was compared with EYLEA in patients with Diabetic Macular Edema. This study demonstrated that there were no clinically meaningful differences between YESAFILI and EYLEA in terms of pharmacokinetics, safety, efficacy, and immunogenicity. Indications and Usage: Treatment with YESAFILI (aflibercept) is for intravitreal injection only. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) Visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) Diabetic Macular Edema (DME) Myopic choroidal neovascularization (myopic CNV) Warnings and Precautions: YESAFILI is contraindicated in patients with ocular or periocular infection, active intraocular inflammation, and hypersensitivity to aflibercept, to any ingredient in the formulation or to any component of the container. Patients may experience temporary visual disturbances after an intravitreal injection with YESAFILI and the associated eye examinations. They should not drive or use machines until visual function has recovered sufficiently. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/ anaphylactoid reactions, or severe intraocular inflammation. Endophthalmitis, retinal detachment, retinal tear, retinal pigment epithelium tear, cataract including traumatic cataract, vitreous hemorrhage and hyphema, may occur following intravitreal injections. Retinal vasculitis and retinal occlusive vasculitis, typically in the presence of intraocular inflammation or treatment with other intravitreal agents. Increases in intraocular pressure have been observed within 60 minutes of an intravitreal injection Please refer to full Product Monograph for YESAFILI for more information. To report SUSPECTED ADVERSE REACTIONS, contact Biocon Biologics at 1-833-986-1468. YESAFILI is a trademark of a Biocon Biologics BIOLOGICS and the Biocon Biologics Logo are trademarks of Biocon Biologics Limited. All other trademarks are the property of their respective owners. About Biocon Biologics Limited: Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve over 5.8 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized nine biosimilars from its portfolio which are addressing the patients' needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: Follow us on X (formerly Twitter): @BioconBiologics and LinkedIn: Biocon Biologics for company updates. For FY24 Integrated Annual Report of Biocon Biologics click here Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: Follow-us on X (formerly Twitter) @bioconlimited and LinkedIn: Biocon for company updates. Forward-Looking Statements: BioconThis press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release. For More Information: Biocon Biologics MEDIA INVESTORS Seema AhujaGlobal Head of Corporate Brand & Head of Communications – Emerging Markets +91 99723 Lance LongwellPublic Relations Lead – Advanced Markets +1 857 270 Saurabh PaliwalHead - Investor RelationsBiocon +91 95383 80801 CONTACT: Lance Longwell Biocon Biologics Ltd 857-270-4391
